CST3 and chronic kidney disease: Moreover, using cystatin-C as a biomarker for chronic kidney disease (CKD) may yield more accurate risk estimates and offer enhanced prognostic value for cardiovascular events and overall mortality, especially in low-risk populations (Rothenbacher et al., 2020).